N-(4-BROMO-2-(2-((6-CHLOROPYRIDIN-3-YL)METHYL)HYDRAZINECARBONYL)-6-METHYLPHENYL)-3-CHLORO-2,2-DIMETHYLPROPANAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CSAWBBTUTLVMTF-UHFFFAOYSA-N
Smiles	Cc1cc(Br)cc(C(=O)NNCc2ccc(Cl)nc2)c1NC(=O)C(C)(C)CCl
InChI	InChI=1S/C19H21BrCl2N4O2/c1-11-6-13(20)7-14(16(11)25-18(28)19(2,3)10-21)17(27)26-24-9-12-4-5-15(22)23-8-12/h4-8,24H,9-10H2,1-3H3,(H,25,28)(H,26,27)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H21BrCl2N4O2
Molecular Weight	488.21
AlogP	3.87
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	7.0
Polar Surface Area	83.12
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	28.0

Assay Description	Organism	Bioactivity
Pesticidal activity against Plutella xylostella (diamondback moth) second-instar larvae grown on cruciferous vegetables leaves leaves as pest mortality at 600 mg/L measured 48 hr post compound exposure	Plutella xylostella	52.0 %
Pesticidal activity against Tetranychus cinnabarinus (carmine spider mite) third- instar larvae grown on Phaseolus vulgaris leaves assessed as pest mortality at 600 mg/L measured 48 hr post compound exposure	Tetranychus cinnabarinus	55.8 %
Pesticidal activity against Aphis gossypii (cotton aphid) third-instar nymphae grown on tender Hibiscus syriacus leaves assessed as pest mortality at 600 mg/L measured 24 hr post compound exposure	Aphis gossypii	33.3 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2230156
PubChem	71513974

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).